← BIOCRYST PHARMACEUTICALS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $22.1m | $50.3m | $26.7m | $114.2m | $272.1m | $504.4m | $304.8m | $110.6m | $104.7m | $89.7m | |
| Prepaid Expense and Other Assets, Current | $1.4m | $1.4m | $2.4m | $4.4m | $5.5m | $10.0m | $12.6m | $19.5m | $13.8m | $17.2m | |
| Short-term Investments | — | — | — | — | — | — | — | $278.3m | $216.1m | $185.0m | |
| Inventory, Net | $500k | — | $1.6m | $0 | $7.0m | $15.8m | $27.5m | $28.7m | $31.3m | $5.4m | |
| Assets, Current | $67.0m | $125.4m | $114.4m | $164.3m | $323.8m | $566.1m | $516.5m | $496.0m | $422.0m | $404.3m | |
| Property, Plant and Equipment, Net | $9.9m | $9.5m | $9.1m | $7.3m | $7.1m | $8.7m | $8.6m | $7.9m | $7.8m | $8.8m | |
| Operating Lease, Right-of-Use Asset | — | — | — | — | — | — | $6.8m | $8.7m | $8.1m | $7.5m | |
| Other Assets, Noncurrent | $3.8m | $2.0m | $978k | $3.6m | $3.8m | $6.5m | $6.8m | $13.1m | $5.2m | $5.7m | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | $8.8m | $6.1m | $4.3m | $22.1m | $8.6m | $29.4m | $50.6m | $57.0m | $79.1m | $106.8m | |
| Accrued Liabilities, Current | $10.8m | $12.7m | $15.9m | $21.4m | $33.9m | $72.7m | $87.6m | $102.9m | $113.3m | $126.4m | |
| Assets | $89.8m | $178.3m | $146.8m | $175.3m | $334.7m | $588.2m | $550.0m | $517.0m | $490.4m | $514.2m | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | — | — | — | $1.8m | $2.4m | $1.1m | $937k | $317k | |
| Accounts Payable, Current | $4.3m | $6.3m | $7.8m | $14.0m | $18.7m | $27.8m | $14.4m | $20.9m | $11.6m | $15.8m | |
| Operating Lease, Liability, Noncurrent | — | — | — | — | — | $6.0m | $5.8m | $8.4m | $7.9m | $8.6m | |
| Deferred Revenue, Current | $2.0m | $8.5m | $221k | $2.1m | $150k | $1.4m | $1.2m | $0 | — | — | |
| Deferred Revenue, Noncurrent | $8.2m | — | — | — | — | — | — | — | — | — | |
| Long-term Debt, Excluding Current Maturities | — | — | — | — | $119.7m | $136.1m | $231.6m | $303.2m | $314.9m | $0 | |
| Liabilities, Current | $54.4m | $74.8m | $69.5m | $92.3m | $105.7m | $103.7m | $105.5m | $150.0m | $160.4m | $196.1m | |
| Deferred Tax Liabilities, Net | — | — | — | — | — | — | $11k | — | — | — | |
| Liabilities | — | — | — | — | — | — | — | — | $966.4m | $633.3m | |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, Issued | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Common Stock, Value, Issued | $738k | $984k | $1.1m | $1.5m | $1.8m | $1.8m | $1.9m | $2.1m | $2.1m | $2.1m | |
| Additional Paid in Capital | $566.9m | $714.9m | $780.4m | $877.3m | $1.0b | $1.1b | $1.2b | $1.2b | $1.3b | $1.4b | |
| Retained Earnings (Accumulated Deficit) | ($566.1m) | ($631.8m) | ($732.0m) | ($840.6m) | ($1.0b) | ($1.2b) | ($1.5b) | ($1.7b) | ($1.8b) | ($1.5b) | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | ($12k) | ($243k) | ($297k) | $39k | $3k | $177k | $26k | $1.3m | $921k | $38k | |
| Stockholders' Equity Attributable to Parent | $1.6m | $83.8m | $49.2m | $38.3m | ($19.3m) | ($107.0m) | ($294.6m) | ($455.5m) | ($475.9m) | ($119.2m) | |
| Liabilities and Equity | $89.8m | $178.3m | $146.8m | $175.3m | $334.7m | $588.2m | $550.0m | $517.0m | $490.4m | $514.2m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.